CDC tells states to prepare distributing potential COVID-19 vaccine as soon as November.
The Centers for Disease Control and Prevention (CDC) tells state health officials in the United States of America to prepare in distributing COVID-19 vaccines to health-care workers and other high-priority groups as soon as November of this year.
Documents from the government were sent to public health officials in all states and territories last week, outlining detailed scenarios for distributing two unidentified vaccine candidates, each requiring two doses a few weeks apart, at hospitals, mobile clinics, and other facilities offering easy access to the first targeted recipients.
Over the past week, both Dr. Anthony S. Fauci and Dr. Stephen Hahn heads the Food and Drug Administration (FDA), said that a vaccine may be available for certain groups before clinical trials have been completed if the data comes back positive.
China to offer potential COVID-19 vaccines to aviation industry workers.
China has recently offered experimental COVID-19 vaccines to aviation industry workers to prevent a possible resurgence as economies reopen.
China, which has four COVID-19 vaccines in the final stage of human trials, launched the emergency use vaccine program in July, hoping to boost the immunity of groups such as border inspectors or medical industry workers.
Although, it is not indicated which vaccine candidates are to be used.
Currently, there are two experimental vaccines, one from Sinovac Biotech Ltd and the other from China National Biotec Group, which have been approved for emergency use in China.
Canada recently secures 114 million doses of potential COVID-19 vaccine.
Canada recently signed agreements in securing up to 114 million doses of potential COVID-19 vaccines by Novavax and Johnson & Johnson.
Novavax’s vaccine has shown results that it is able to be manufactured at a faster rate as compared to some other types of vaccine but generally doesn’t produce as strong an immune response as some other potential options. The company has released promising results of the potential vaccine, which showed it produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients. The company added that should the vaccine be deemed safe and effective, it can be expected to be available to Canadians as early as the second quarter of 2021.
Meanwhile, Johnson & Johnson’s vaccine candidate, Ad26.COV2.S, targets the virus in a completely different way than the Novavax candidate, known as a non-replicating viral vector vaccine, viruses are genetically engineered so they can’t replicate and cause disease then injected into the body to induce an immune response.